1. Home
  2. DVAX vs WBI Comparison

DVAX vs WBI Comparison

Compare DVAX & WBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DVAX
  • WBI
  • Stock Information
  • Founded
  • DVAX 1996
  • WBI 2016
  • Country
  • DVAX United States
  • WBI United States
  • Employees
  • DVAX N/A
  • WBI N/A
  • Industry
  • DVAX Biotechnology: Pharmaceutical Preparations
  • WBI Oilfield Services/Equipment
  • Sector
  • DVAX Health Care
  • WBI Energy
  • Exchange
  • DVAX Nasdaq
  • WBI Nasdaq
  • Market Cap
  • DVAX 1.2B
  • WBI 1.1B
  • IPO Year
  • DVAX 2004
  • WBI 2025
  • Fundamental
  • Price
  • DVAX $10.44
  • WBI $24.23
  • Analyst Decision
  • DVAX Buy
  • WBI Buy
  • Analyst Count
  • DVAX 4
  • WBI 8
  • Target Price
  • DVAX $26.50
  • WBI $27.25
  • AVG Volume (30 Days)
  • DVAX 1.3M
  • WBI 734.9K
  • Earning Date
  • DVAX 11-05-2025
  • WBI 11-12-2025
  • Dividend Yield
  • DVAX N/A
  • WBI N/A
  • EPS Growth
  • DVAX N/A
  • WBI N/A
  • EPS
  • DVAX N/A
  • WBI N/A
  • Revenue
  • DVAX $316,268,000.00
  • WBI $645,712,000.00
  • Revenue This Year
  • DVAX $23.23
  • WBI N/A
  • Revenue Next Year
  • DVAX $16.57
  • WBI N/A
  • P/E Ratio
  • DVAX N/A
  • WBI N/A
  • Revenue Growth
  • DVAX 26.66
  • WBI N/A
  • 52 Week Low
  • DVAX $9.20
  • WBI $22.22
  • 52 Week High
  • DVAX $14.63
  • WBI $27.12
  • Technical
  • Relative Strength Index (RSI)
  • DVAX 58.99
  • WBI N/A
  • Support Level
  • DVAX $10.03
  • WBI N/A
  • Resistance Level
  • DVAX $10.59
  • WBI N/A
  • Average True Range (ATR)
  • DVAX 0.22
  • WBI 0.00
  • MACD
  • DVAX 0.06
  • WBI 0.00
  • Stochastic Oscillator
  • DVAX 81.25
  • WBI 0.00

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

About WBI WaterBridge Infrastructure LLC Class A Shares Representing Limited Liability Company Interests

WaterBridge Infrastructure LLC is integrated, pure-play water infrastructure company with operations predominantly in the Delaware Basin, the prolific oil and natural gas basin in North America. It operates the largest produced water infrastructure network in the United States through which it provides water management solutions to oil and natural gas E&P companies under long-term contracts, which include gathering, transporting, recycling and handling produced water. It also operate two energy waste management facilities for the disposal of non-hazardous waste resulting from oil and gas E&P activities, branded under Desert Environmental. The transportation, treatment and handling of produced water is crucial to oil and natural gas production.

Share on Social Networks: